Loading patent…
AssigneeSchering Corpration, a New Jersey corporation
InventorsWei Wang, Elizabeth R. Oldham, Hortensia Soto, Ying Liu, Susan A. Hudak, Bernhard Homey, Janine M. Morales, Sirid-Aimee Kellermann, Leslie M. McEvoy, Edward P. Bowman, Albert Zlotnik
Estimating the term…
Agonists or antagonists of CTACK or Vic chemokines, and various methods of use in dermatological and related applications are provided. In particular, the method makes use of fact that the CTACK or Vic chemokines are specifically capable of inducing movement of a skin cell subset. Moreover, matching of ligand with GPR2 receptor in mammals provides methods of use.
A method of modulating movement of a cell within or to the skin of a mammal, said method comprising administering to said mammal an effective amount of:
A method of purifying a population of cells, said method comprising contacting said cells with CTACK or Vic, thereby resulting in the identification of cells expressing a receptor for said CTACK or Vic.
A method of producing a ligand:receptor complex, comprising contacting:
A method of modulating physiology or development of a GPR2 expressing cell comprising contacting said cell to an agonist or antagonist of a mammalian Vic or CTACK, wherein one of said GPR2 receptor or said agonist or antagonist is recombinant or purified.
A method of testing a compound for ability to affect GPR2 receptor-ligand interaction, said method comprising comparing the interaction of GPR2 with Vic or CTACK in the presence and absence of said compound.
A primate GPR2, comprising sequence of MGTEVLEQ (see SEQ ID NO:
An antibody which binds selectively to MGTEVLEQ (see SEQ ID NO:
A method of treating a patient suffering from a skin disorder comprising administering an effective amount of an antagonist against GPR2, Vic, or CTACK.
Dependencies are inferred from the claim text.